

Chammas & Marcheteau advises Eyevensys on its €27 million fundraising

Chammas & Marcheteau advised Eyevensys on its €27 million fundraising, led by Boehringer Ingelheim and joined by the funds Global Health Sciences and Pureos Bioventures, with the continuous support of its historical shareholders Pontifax, Bpifrance, CapDecisif and Inserm Transfert.

Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology which enables the sustained intraocular production of therapeutic proteins for the treatment of a broad range of ophthalmic diseases.

The **Chammas & Marcheteau** team was composed of partner **Denis Marcheteau** and associates **Romain Penloup** and **William Ducrocq-Ferré**.

About Chammas & Marcheteau:

Chammas & Marcheteau is a Paris-based independent law firm that advises companies, investment funds and entrepreneurs on their transactions and development strategies in France and abroad. With 35 specialists in business law, including 9 partners, the firm offers its clients expertise in Mergers & Acquisitions, Private Equity, Funds and Financial Services, Tax, and Intellectual Property and Information Technology. The Firm has a rapidly growing international activity, including in Africa.

Contact:

Benoîte Crochet
+33 6 75 44 03 52
bcrochet@lcdm.law